Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of Bellerophon Therapeutics stock opened at $0.06 on Wednesday. The stock has a market capitalization of $684,880.00, a price-to-earnings ratio of -0.07 and a beta of 0.69. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $11.15. The company has a 50-day simple moving average of $0.06 and a two-hundred day simple moving average of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.